An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
about
Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantationManagement of HBV Infection in Liver Transplantation PatientsPrevention and Treatment of Recurrent Hepatitis B after Liver TransplantationKASL clinical practice guidelines: management of chronic hepatitis BProphylactic managements of hepatitis B viral infection in liver transplantationChange of strategies and future perspectives against hepatitis B virus recurrence after liver transplantationImpact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantationProphylaxis and treatment of hepatitis B recurrence after liver transplantation in the antiviral era.Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation.Clinicopathological features of hepatitis B virus recurrence after liver transplantation: eleven-year experience.Large fragment pre-S deletion and high viral load independently predict hepatitis B relapse after liver transplantation.Hepatitis B and C in the liver transplant recipient: current understanding and treatment.Chronic hepatitis B: current and future treatment options.Management of viral hepatitis in liver transplant recipientsHepatitis B: progress in the last 15 years.Prevention of recurrent hepatitis B post-liver transplantation.Network meta-analysis on prophylactic regimens against recurrent hepatitis B virus infection after liver transplantation.Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Liver transplantation in adults: Choosing the appropriate timingPrevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analoguesReview article: hepatitis B and liver transplantation.Prevention of hepatitis B virus recurrence after liver transplantation.Monoclonal antibodies for prophylaxis and therapy of infectious diseases.Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitroQuasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach.Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysisHepatitis B immunoglobulin in preventing reinfection following liver transplantation.Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation.Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation.The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation.Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review.Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation.Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation.Hepatitis B immune globulin in liver transplantation prophylaxis: an update.Hepatitis B and C in liver transplantation: new strategies to combat the enemies.Hepatitis B recurrence after liver transplantation: a single center experiences and review the literature.Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues.Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity.HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation.
P2860
Q24234338-07D03949-C467-4AED-8A61-DBBE59AE6CE2Q24529103-75C22A34-7D64-42AA-8CA3-FAEE32CF23E8Q26751777-D9200088-92D1-43E4-86DA-62BF11CF77FDQ26752475-F0EC5754-3308-4DB1-B735-8BB840D8F62CQ26772340-22855C8D-389E-4B44-B0D4-6EFEB5C82CCCQ26784241-D087AD70-E1CD-4B7F-9C28-379236A2B43EQ30431207-2FF35F88-682F-4A34-A8D9-25A1536D35D2Q33207885-29A38F8E-574C-4E71-86B3-B29C2E10DB04Q33624284-E772F848-7B15-4B61-A523-B1F57B1C8FBAQ34029115-0BD74FD9-159F-45B1-9A86-FBBD4697A3CDQ34171703-F25305C9-EE0A-49B1-B84C-4B03A0DF7EE0Q34426421-A663CAF1-C1B7-4A42-8BB8-751E6B80BB9AQ34687438-0D59D1A7-8C3C-4DAB-81D4-685E96F88122Q34779730-5E8D7C17-D935-4BB6-BD25-C472A8C51F1AQ34936238-596815F7-11DC-442A-BA5F-C13828B195C0Q34936261-7CDA8C9A-E80C-419D-8E30-07072F80CBF8Q35103135-7FB62CF6-BEB0-484E-B67F-A1EAA6EF4138Q36028324-43E15BBD-3972-49AA-BD56-EFEB32BCEB0DQ36153966-6E0A1AE3-3641-43E3-B96A-AB817EFDB3DCQ36220176-1CD90C27-05ED-47D3-AC4B-0A15F748491FQ36442537-E29BE7EB-0C17-4E83-AE1E-F9EA492ECE31Q36447557-B96A58EF-A130-4C46-847E-C5D7A32053A4Q36652077-BB2B5238-58DD-4A6D-8B4D-BF96E523AAF6Q36989900-0E55D19C-E50C-47AB-AAEE-18DABF11C163Q37137539-8F63B241-859E-4103-9562-6A1FA666CAA4Q37285249-51407D3F-5B02-4624-BCB2-9CC7E36AD012Q37310932-763F210E-E7BB-43DF-A66B-AF168866EAB2Q37432104-690B5FCE-2389-4634-A146-BA9C169D0B28Q37495757-71E4A839-AA14-4310-95D3-06952E033014Q37760897-A3086D3A-8260-4EF5-8BFD-8D713BBA8CDEQ37870833-9A1628A3-C8BD-4487-A736-C1E1B3213075Q37886893-705B9DD2-22B3-4C4B-BC2F-412F41BF3524Q37905782-B2F251EB-37AA-4D4F-A770-03B131968A60Q37982346-7DE5E630-6CBE-4B9C-9435-CA1AB60A7B16Q38006958-45DE281E-A533-4341-8530-BC9A948E9E8EQ38067343-87CF836D-4E2C-4B8A-9A54-6C123D1F9140Q38088688-02483421-925D-4BCA-A389-7D777CC379C3Q38121508-A42FD2F7-6AB2-48F9-B250-67D0DE1DC92FQ38137238-306F00B5-C6F2-4314-A770-A099891F4130Q38218762-E2D53AE0-C8A4-4826-A860-52EFA9B58847
P2860
An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
An efficacy and cost-effective ...... B immune globulin monotherapy.
@ast
An efficacy and cost-effective ...... B immune globulin monotherapy.
@en
An efficacy and cost-effective ...... B immune globulin monotherapy.
@nl
type
label
An efficacy and cost-effective ...... B immune globulin monotherapy.
@ast
An efficacy and cost-effective ...... B immune globulin monotherapy.
@en
An efficacy and cost-effective ...... B immune globulin monotherapy.
@nl
prefLabel
An efficacy and cost-effective ...... B immune globulin monotherapy.
@ast
An efficacy and cost-effective ...... B immune globulin monotherapy.
@en
An efficacy and cost-effective ...... B immune globulin monotherapy.
@nl
P2093
P356
P1476
An efficacy and cost-effective ...... B immune globulin monotherapy.
@en
P2093
D G Farmer
L Goldstein
R M Ghobrial
P304
P356
10.1053/JLTS.2000.18702
P577
2000-11-01T00:00:00Z